FWIW, I reached out to IR last night and got the response below very late last night. I give Revance IR credit for making the effort to support their shareholders.
We share your disappointment with the current share price and are busy both running the business and communicating our truly exciting story to investors.
Internally, we are fully focused on the BLA filing, planning our launch for 2020 and enrolling patients in 5 different clinical trials.
Externally:
- We secured 2 major articles over the past week - one in the SF Business Journal (focused on our move into therapeutic indications) and another in the Wall Street Journal (focused on the threats to Allergan's Botox).
- Early in the week, we issued 2 press releases - one on a presentation of our SAKURA data at a major global medical congress in Monaco and the other on our new VP of Marketing from Allergan.
- Yesterday, we spoke at the Needham Healthcare Conference and met with 7 potential investors
- Today and tomorrow we are on a roadshow to see more than 10 potential investors in NY, Philadelphia and Baltimore.
- Also today, a small group of investors got to visit one of our SAKURA investigators at her office in Beverly Hills to see how see runs her practice and hear what she thought of the new neuromodulators -- such as DAXI -- on the horizon.
- Next week, one of our sell-side analysts is bringing 7 investors to Revance for a presentation and tour of our manufacturing facility.
Feedback we get indicates the company stock is in the doldrums as investors await the next big catalyst before they feel they need to jump in. We expect our next major announcement may be regarding our biosimilar agreement with Mylan, as we await the official meeting minutes from the FDA so we can finalize a potential clinical plan and timeline.
Hope that update helps!
News 
Market Data 
Discover 
AI
